TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
This is a discussion on TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab within the Updates from the Technology Assessment Authorities forum, part of the Industry News and Updates category; The summary for the published technology appraisal on Leukaemia (chronic lymphocytic, relapsed) - rituximab. It links to the published guidance and ...
|
|||||||
| Register | Help | Members List | Mark Forums Read |
07-27-2010, 08:25 PM
|
|||
|
|||
TA193: Leukaemia (chronic lymphocytic, relapsed) - rituximab
The summary for the published technology appraisal on Leukaemia (chronic lymphocytic, relapsed) - rituximab. It links to the published guidance and key documents.
More... 
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| TA29: Leukaemia (lymphocytic) - fludarabine | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA70: Leukaemia (chronic myeloid) - imatinib | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA119: Leukaemia (lymphocytic) - fludarabine | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA174: Leukaemia (chronic lymphocytic, first line) - rituximab | industry_news | Updates from the Technology Assessment Authorities | 0 | 04-01-2010 12:51 PM |
| TA174: Leukaemia (chronic lymphocytic, first line) - rituximab | industry_news | Updates from the Technology Assessment Authorities | 0 | 07-21-2009 08:58 PM |
© 2008 DrugManagementForum™ powered by |
 |